Business Wire

CRESTBRIDGE

25.7.2022 16:48:05 CEST | Business Wire | Press release

Share
Crestbridge Appoints New Luxembourg Country Head, as the Business Advances Its Leading Position Locally and Internationally

Crestbridge, the agile alternative for private equity and real estate administration solutions, today announced the appointment of Anne Catherine Grave as Country Head of Luxembourg.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220725005497/en/

Based in Luxembourg, Anne Catherine will be responsible for leading the business in the region and building on its reputation as a leading service provider for fund managers.

Since establishing a presence in Luxembourg 11 years ago, Crestbridge has continued its commitment to quality, evolving its service proposition in line with the jurisdiction’s own exponential growth. This is testament to Crestbridge’s popularity amongst fund managers, driven by the firm's expertise in management company services, private equity, real estate, private debt and venture capital.

Anne Catherine’s appointment adds further weight to Crestbridge’s highly experienced Luxembourg team, who provides global, comprehensive support to fund managers. This includes managing the administrative, accounting, reporting, residency and governance needs of a broad range of fund structures throughout their lifecycles.

Prior to joining Crestbridge, Anne Catherine was the Partner in charge of Corporate Secretarial Services in Deloitte in Luxembourg. She has over 20 years' experience in Private Equity and Real Estate sectors.

Anne Catherine gained her extensive experience as part of the Management/Executive Committees of Arendt Services in Luxembourg, as well as in her position as Executive Director of Bedell (which became Ocorian), a Luxembourg Trust & Fund business of a Jersey Group. In both positions, she served as board members of various regulated and non-regulated clients’ entities. Anne Catherine’s area of activities included the compliance, corporate, governance, tax, internal control and risk management functions. She started her career as tax advisor in Ernst & Young in Luxembourg and New York, before transitioning into a Senior Tax Lawyer position at a Luxembourg Law Firm, Arendt.

Anne Catherine holds masters’ degrees in economics and in International & European law, a post-graduate diplomas in Political Sciences as well as in International Business Law. She is also qualified as a Certified International Control Specialist and has a qualification in risk management. She was a Chartered Accountant in Luxembourg and a qualified attorney in France and Luxembourg. Anne Catherine was the Chair of the ILA Company Secretary and Governance Officer Committee for 4 years. She remains an active member of such committee and is a speaker for the ILA Company Secretary and Governance Officer Committee certification.

Michael Johnson, Group Head of Institutional Services, Crestbridge, said:

“I'm delighted to welcome Anne Catherine to the team and am delighted that Crestbridge continues to be a business where top, global talent comes to work and thrive. Anne Catherine will be leading some of the best talent available in the region, people who are focused on delivering exceptional service and innovative solutions to our global client base. Anne Catherine offers the team not only considerable technical expertise but vast knowledge, having worked with some of the biggest names in the industry. I look forward to her playing a vital role in leading and driving forward our Luxembourg and international business.”

-ENDS-

Notes to editors

  • We are a leading global administration, management & corporate governance solutions business.
  • We provide a broad range of outsourced fiduciary, administrative, accounting, and compliance services globally – our expertise spans services, asset classes, and jurisdictions. Since 1998, we have been putting our insight and experience to work for clients who include leading corporations, sovereign wealth funds, investor groups, asset managers, and ultra-high net worth families.
  • Crestbridge employs over 500+ people and has nine international offices: Bahrain, Cayman, Ireland, Jersey, London, Luxembourg, New Jersey, New York, and Southampton.
  • We are regulated in our locations (see here for more details)

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse

Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release

Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye